subject: Stock Updates On Heb, Exxi And Crwe From Pennytobuck.com [print this page] Crown Equity Holdings IncCrown Equity Holdings Inc. (OTCBB:CRWE.OB) recently announced that its sales this year have already surpassed $1,000,000. This compares to $232,510 for the three quarters ending September 30, 2009 and $ 659,907 total sales for the year 2009.
Crown Equity Holdings Inc. has expanded its internet footprint internationally to include the following 19 countries: Argentina, Australia, Brazil, Canada, China, France, Germany, Hong Kong, India, Ireland, Italy, Japan, Korea, Mexico, New Zealand, Singapore, Spain, Taiwan and the UK.
Crown Equity Holdings, Inc. is a company utilizing todays technology to advertise, promote and market public companies globally. CRWEs proprietary network technology allows their publishing department to get their content to millions of readers daily across the world. CRWE publishes financial content to all the major countries and covers all the accredited stock exchanges.
Crown Equity Holdings Inc. is a consulting organization which provides and assists small business owners with the knowledge required in taking their company public, and has re-focused its primary vision with its aligned group of independent website divisions to providing media advertising services, as a worldwide online media advertising publisher, dedicated to the distribution of quality branding information, as well as search engine optimization for its clients.
Energy XXI (Nasdaq:EXXI) announced it will host a conference call on Wednesday, Sept. 8, 2010, at 9 a.m. CDT (3 p.m. London time) to discuss fiscal 2010 year-end and fourth-quarter financial and operating results for the period ended June 30, 2010. Results will be released through global newswire services the prior evening and will be available at www.EnergyXXI.com.
To actively participate on the conference call, please call the dial-in number below about 5 minutes before the scheduled start time. Those who wish to view the presentation materials, or to participate in listen-only mode, should access the event through the company's web site, www.EnergyXXI.com. A replay of the call will be archived and available on the web site following the live call.
Energy XXI is an independent oil and natural gas exploration and production company whose growth strategy emphasizes acquisitions, enhanced by its value-added organic drilling program. The company's properties are located in the U.S. Gulf of Mexico waters and the Gulf Coast onshore. Seymour Pierce is Energy XXI's listing broker in the United Kingdom. To learn more, visit the Energy XXI website at www.EnergyXXI.com.
Hemispherx Biopharma, Inc. (AMEX:HEB) today announced that, as result of court mediation proceedings, it has entered into a written agreement in principle with the Court-appointed lead plaintiffs to settle all of the currently pending securities class actions consolidated in the U.S. District Court for the Eastern District of Pennsylvania. The proposed settlement requires formal court approval. The class actions have been stayed by the Court pending those mandatory procedures needed to formalize and approve the settlement. The settlement will be paid from HEB's insurance coverage and will not result in the payment of any funds by the Company. Furthermore, the settlement expressly is not an admission of any culpability by Hemispherx or its officers. Thomas K. Equels, General Counsel, stated: "We at Hemispherx look forward to Court approval of this settlement. Our team will be glad to have these class actions behind us so that we can focus our time and resources on the important work of new drug development related to Ampligen for CFS, important flu related clinical trials, and the manufacturing and marketing of our FDA approved anti-viral Alferon."
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(TM) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen(R) and Alferon LDO(TM). Ampligen(R) represents experimental nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes agents for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(TM)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States. For more information please visit www.hemispherx.net
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
